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● Outline varying diagnostic criteria
● Briefly review pathophysiology and diagnostic approach
● Review primary care management of PCOS symptoms
● Summarize role of PCP for clinical monitoring 
● Explore influence of PCOS on fertility and pregnancy
I won’t be covering:
Advanced infertility treatment
Management of Diabetes
Management of complications of 
pregnancy
Advanced workup for endocrine 
disorder such as Cushings, CAH, 
Acromegaly
Psychological Impact of PCOS
Our Patient
CM is a 26 yo patient (she/her) with no significant PMH coming in for a 
routine gyn visit. She is due for her pap and she reports irregular periods 
occurring every 1-3 months. She also notes that she has noticed a lot more 
facial hair develop along her chin over the past year which is really 
bothering her.
VSS. 
Physical exam remarkable for BMI 33, mild acne along jawline, and notable 
facial hair on upper lip, outer cheeks, jawline and upper neck. 
Multiple striae are observed on abdomen and her chest. 
GU exam is normal, anteverted uterus on bimanual exam. Pap performed. 
Remainder of exam within normal limits. 
Definition: 
Most common endocrinopathy of reproductive-age patients with ovaries with 
a constellation of symptoms including a combination of irregular menses, 
hyperandrogenism, insulin resistance/hyperinsulinism, obesity, and potential 
changes to ovarian morphology. 
Precise etiology is unknown but thought to be a complex interplay 
of genetics and environment leading to insulin resistance and 
ovarian overproduction of androgens.
7-10%
 Of reproductive-age people with ovaries have this condition 
(approximately 5 million people in the US)
PCOS linked to multiple comorbidities!
We have many ways to treat it. 
Diagnostic Schema
Signs & Symptoms NIH Criteria (1990) Androgen Excess 
Society (2006)
Rotterdam Criteria 
(2003) - 2 out of 3 
required for Dx
Hyper androgenism Required Required Not required
Oligomenorrhea
Amenorrhea
Required Not required Not required
Polycystic ovaries by 
ultrasound diagnosis
Not required Not required Not required
Adapted from ACOG Practice Bulletin #194
NIH Criteria (1990)
Exclude other causes of hyperandrogenism and anovulation. 
Oligo/Anovulation : unpredictable menses <21 days apart or >35 days apart (but 
overall less than 6 months apart), 2 years after menarche
PLUS
Clinical or lab findings of hyperandrogenism 
Rotterdam Criteria (2003) 
Exclude other causes of hyperandrogenism and anovulation. 
ANY TWO of the following:
- Polycystic ovaries on transabd or transvaginal ultrasound
- Chronic anovulation or oligovulation
- Hyperandrogenism
More sensitive criteria overall! 
Androgen Excess Society (2006)
Requires clinical or lab findings of hyperandrogenism 
AND 
Anovulation/Oligovulation or polycystic ovaries
What about adolescent patients?
Wait until  at least 2 years after menarche
Recommend all three criteria for diagnosis by Endocrine Society













Clinical Findings on Physical Exam
- Elevated BMI, higher sensitivity with BMI >30 
- Waist circumference >35 inches 
- Presence of features suggestive of 
hyperinsulinism or hyperandrogenism: 
- Acne
- Hirsutism
- Male pattern alopecia
- Acanthosis Nigricans
Courtesy of MerckManuals
What initial labs would 
you order for our patient?




- Fasting 17- OH progesterone
- If >200 ng/dL then ACTH stim test
Other tests: 
- Hemoglobin A1c or two hour glucose 
tolerance test 
- Lipids
- Total testosterone and SHBG or 
bioavailable and free testosterone
- DHEAS (in rapid virilization - adrenal?)
- Transvaginal Ultrasound
Ultrasound Findings
Case courtesy of Dr J. Ray Ballinger, Radiopaedia.org, rID: 23638





>8 yrs post menarche & using TVUS:
- Follicle # per ovary >20 and/or
- Ovarian Volume >10cc
Transabdominal scanning - Ovarian 
volume threshold >10cc
*TVUS and abd US should not be used in 
adolescent females given multi-follicular 
ovaries in this life stage.
Other morphology: 
- Peripheral location of follicles (string 
of pearls)
- Hyperechoic central stroma
- Follicles of similar size measuring 
2-9mm
Courtesy of AAFP
Are FSH & LH 




Combined OCPs, combined OCPs, combined OCPS!
- Reduce circulating free androgens and decrease hyperandrogenism 
symptoms
- Decrease risk of endometrial cancer
- Creates predictable monthly withdrawal bleeding during placebo
Proven to be more effective than progestin only methods including: 
- Depot (medroxyprogesterone acetate)
- PO medroxyprogesterone acetate
- Progestin containing IUD 




- Spironolactone (50-200mg BID)
- Flutamide (200mg)** - androgen receptor agonist




- Spironolactone (50-200mg BID)
- Flutamide (250 mg BID)**
Dermatological Manifestations
Hirsutism- prevalence of 70% of patients 
- Combo OCPS
- Spironolactone 25-100mg daily
- Thiazolididones (pioglitazone, rosiglitazone)
- Laser therapy 
- Laser therapy + Elfornithine
Weak level of data on Finasteride and Flutamide
Metabolic 
Obesity
- Weight Loss has the best efficacy for almost all symptoms of PCOS
- Decreases circulating androgens by increasing SHBG
- Just a 5% decrease in body weight showed improvements in ovulation 
Insulin Resistance
- Metformin 750-1000mg BID plus lifestyle modifications
Integrative Approaches to PCOS
- Diet changes for weight loss
- Stress reduction using exercise, meditation, acupuncture
- Supplements: 
- Adaptogens: Ashwaganda, holy basil, rhodiola, and maca root
- Licorice - lowering testosterone levels (avoid in HTN)
- Inositol for non-obese patients
Limited data on supplements effectiveness. Great data on exercise and weight loss 
as effective method. 
Wrapping up our case…
CM found to have A1c 6.0, normal lipid panel, 
normal TSH, prolactin, 17-OH progest, normal 
ovaries on ultrasound
- Started on metformin 500mg BID
- Combined oral contraceptive pill 
- Counseled on weight loss and lifestyle 
modifications
Case #2
PC is a 31 yo patient (she/her)  presenting with concerns for 
infertility. She and her partner have been trying to conceive 
for 9 months. She has hx of PCOS, on metformin 500mg BID, 
On combo OCPs (stopped 9 months ago). 
BMI of 32, A1c 5.9%, Lipids with total cholesterol 220, trigly 
normal. 
How do you counsel her?
Two thirds
Of people with PCOS are able to conceive within one 
year without any medical intervention. 
Infertility and PCOS
- Weight Loss 
- Metformin 500- 1000mg BID**
- Ovulation Induction
- Early A1c at beginning of pregnancy, early GTT (20-24 
weeks) 
Ovulation Induction 
- Clomiphene - selective estrogen receptor modulator 
- 50-100mg daily for 5 days on day 3-5 of cycle
- Letrozole - non steroidal competitive inhibitor of aromatase
-  2.5-7.5 daily for 5 days
- associated with higher live-birth rates and ovulation rates compared in 
clomiphene 
- Metformin for fertility is controversial 
- 2012 Cochrane study refuted this though widely used
Complications in pregnancy
● Increased risk of preterm delivery
● Increased risk of gestational diabetes
● Increased risk of hypertensive disorders of pregnancy
Role of the PCP…
We’ve touched on this a bit
Diabetes & PCOS
- Four-fold risk of type 2 diabetes in women with PCOS
- Metformin shown to improve glucose tolerance, decrease circulating 
androgen 
- Thiazolidinediones as well but has weight gain side effect 
Dyslipidemia & PCOS
- 70% of people with PCOS have dyslipidemia 
- Emerging research about role of statins in reducing cardiovascular effects of PCOS 
on patients
- Long term effects of preventing CVD in young women with PCOS is unknown
Endometrial Cancer & PCOS
- Recommend against routine ultrasound
- Management: OCPs for prevention of endometrial hyperplasia
- Endometrial biopsy can be done when indicated 
- Rate of endometrial cancer 2.7 times as high in patients with 
PCOS compared to general population 
1. Monitor for insulin resistance q1-3 years 
2. Check lipids q2 years 
3. Use metformin and statins when indicated 
4. Counsel on fertility early
5. Screen for psychological effects: depression, 
anxiety, sleep disturbance
6. Screen for OSA
7. Later in life, screen for NAFLD
Decrease metabolic syndrome and cardiovascular 
Sequelae 
Summary
1. PCOS is prevalent and treatable!
2. Diagnosis is based on the exclusion of other causes and can be made clinically (you 
don’t always need the ultrasound) 
3. Treat the symptoms
4. Lifestyle modifications go a long way 
5. Weight loss (even 5%)  is the most effective treatment for every complications of 
PCOS
6. Combined OCPs are your first line for menstrual irregularities and derm 
manifestations
7. Goal is to decrease the cardiovascular and metabolic sequelae of PCOS
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